PatientsVille.com Logo


Orlistat Medical Research Studies

Up-to-date List of Orlistat Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Orlistat Medical Research Studies

Rank Status Study
1 Not yet recruiting Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.
Conditions: Obesity;   Overweight
Intervention: Drug: Alli® 60 mg
Outcome Measures: To estimate the proportion of Alli® purchasers with a BMI <28 kg/m2.;   To estimate the proportion of Alli® purchasers aged <18 years.;   To estimate the proportion of Alli® purchasers with contraindications to use (ciclosporin use, chronic malabsorption syndrome, cholestasis, pregnancy, breastfeeding, warfarin use).;   To characterise the demographic characteristics of Alli® purchasers in the EU and their patterns of previous use of over-the-counter (OTC) Orlistat (defined as Alli® capsules or a generic equivalent, or alli chewable tablets).;   To estimate the proportions of Alli® purchasers who have previously used OTC Orlistat and who have a history of kidney disease or who are taking levothyroxine.;   For Alli® purchasers who have previously used OTC Orlistat, descriptive data on the daily dose taken (number of capsules [or tablets]) will be collected.;   To provide a descriptive comparison between the results of this survey and the previous surveys.
2 Not yet recruiting Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Condition: Type 1 Hyperlipoproteinemia
Interventions: Drug: SLx-4090 placebo;   Drug: Orlistat Placebo;   Drug: Orlistat;   Drug: Slx-4090
Outcome Measure: Change in serum triglycerides from baseline for each crossover arm phase of placebo/placebo, Orlistat/placebo, Orlistat/SLx-4090, SLx-4090/placebo
3 Not yet recruiting Evaluation of Orlistat Versus Placebo for Adult Obesity Treatment
Condition: Obesity
Interventions: Drug: Orlistat 60 mg;   Other: Placebo
Outcome Measures: Efficacy of Orlistat 60 mg compared to placebo in obesity treatment based on weight loss and abdominal adiposity during 24 weeks.;   Adverse event incidence of Orlistat 60mg when used for weight loss in adults
4 Unknown  Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
Conditions: Obesity;   Insulin Resistance;   Metabolic Syndrome;   Hepatitis C
Interventions: Drug: Orlistat;   Behavioral: Dietary and Lifestyle modification educational sessions
Outcome Measures: HCV RNA;   Body weight;   waist circumference;   skin fold thickness;   HOMA, IR
5 Unknown  Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor
Condition: Obesity
Interventions: Dietary Supplement: Control;   Dietary Supplement: Capolac;   Dietary Supplement: Flax fiber;   Dietary Supplement: Capolac+Flax fiber
Outcome Measures: Ratings of gastrointestinal comfort;   Total fecal fat excretion;   Total, LDL and HDL cholesterol;   Ratings of quality of life;   Body weight;   Waist and hip circumference;   food intake;   Habitual intake of dietary fiber and calcium
6 Unknown  Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
Conditions: Type 2 Diabetes;   Gastric Banding
Interventions: Drug: Liraglutide;   Drug: Orlistat;   Drug: Liraglutide + Orlistat
Outcome Measures: Type 2 diabetes remission;   Whole body insulin sensitivity;   GLP-1 response;   First Phase Insulin secretion
7 Recruiting Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea
Conditions: Obesity;   Diabetes;   Obstructive Sleep Apnea
Interventions: Other: Ketogenic diet;   Drug: Orlistat;   Other: Standardized diet
Outcome Measures: Change of body mass index from baseline in 9 months period;   Change from baseline in glucose blood level in patients with diabetes mellitus in 9 months.;   Change of apnea/hypopnea index in patients with obstructive sleep apnea in patients with obesity;   To evaluate safety of ketogenic diet as a treatment of obesity.
8 Unknown  Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Conditions: Obesity;   Metabolic Syndrome X
Interventions: Drug: Metformin;   Drug: Orlistat;   Drug: Topiramate;   Drug: Placebo
Outcome Measures: Weight (change from baseline);   Brachial artery flow mediated dilatation (change from baseline);   Number of subjects with mild, moderate and serious adverse events.;   Systolic and diastolic systemic arterial pressure (change from baseline);   Fasting lipids, glucose and other biomarkers of obesity risk (change from baseline);   Mood, anxiety, quality of life and cognitive function (change from baseline);   Body fat distribution (change from baseline);   Pulse wave velocity (PWV) and aortic augmentation pressure (change from baseline);   Peripheral arteriolar tonometry
9 Not yet recruiting Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Condition: Type II Diabetes in the Not so Obese
Interventions: Procedure: Roux-en-Y Gastric Bypass (RYGB);   Drug: Incretin analogues;   Drug: Xenical
Outcome Measures: Number of subjects achieving HBA1c of 6% without diabetic medication;   Number of subjects achieving systolic BP <130mm hg without antihypertension medication;   number of subjects achieving LDL level of <100mg/dl without lipid lowering medication;   fasting plasma glucose;   Fasting Insulin;   serum c-peptide level;   serum lipid levels;   C-reactive protein level;   change in medications usage;   changes in gut hormones levels;   changes in metabolic hormones level;   health resource utilisation;   HOMA-IR;   Blood Pressure measurement;   number of adverse events;   Weight loss
10 Unknown  Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial
Conditions: Chronic Kidney Disease;   Obesity
Interventions: Procedure: laparoscopic sleeve gastrectomy;   Behavioral: weight management program
Outcome Measures: Measured glomerular filtration rate (renal function) using the iohexol clearance method in patients with stages 3-4 chronic kidney disease;   Composite end point of death and cardiovascular outcomes (stroke, myocardial infarction or congestive heart failure hospitalisation);   Quality of life and anxiety and depression assessment;   Urinary albumin to creatinine ratio and protein to creatinine ratio;   Body composition (weight, BMI, waist and hip circ, BIA);   Insulin resistance (HOMA method);   Serum adiponectin, leptin, IL-6, TNF-α, hs-CRP, fetuin a;   Urinary markers IL-6, MCP-1, IL-1β, RBP, NAG;   Endothelial function (flow mediated dilatation)
11 Not yet recruiting Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population
Conditions: Cardiovascular Disease;   Type 2 Diabetes;   Asthma;   Allergy;   Osteoporosis
Outcome Measures: 5-year change in prevalence of biomarkers of chronic diseases (e.g. diabetes, asthma, allergy) and micronutrient status (e.g. vitamin D status).;   significant interaction (on a additive scale) between Vitamin D status and genetic variants in the Vitamin D receptor in relation to selected chronic disease biomarkers
12 Unknown  COPD Rehabilitation in Primary and Secondary Health Care
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Procedure: pulmonary rehabilitation programme
Outcome Measure:
13 Unknown  Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Procedure: Patient education and disease management
Outcome Measures: the number of readmissions for chronic obstructive pulmonary disease;   the duration of admissions for chronic obstructive pulmonary disease
14 Unknown  Reduction of Sitting Time: Sedentarism Intervention Trial
Conditions: Life Style;   Physical Activity;   Sedentary Behavior
Intervention: Behavioral: Life style intervention
Outcome Measures: Objectively measured sitting time;   High density lipoprotein (HDL)
15 Unknown  Optimizing the Effect of COPD Rehabilitation
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: follow-up rehabilitation of participants with COPD
Outcome Measures: Disease specific Quality of Life;   Work Capacity;   Number of days admitted to hospital

These studies may lead to new treatments and are adding insight into Orlistat etiology and treatment.

A major focus of Orlistat research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Orlistat